Detection of a single pulmonary nodule (SPN) is usually incidentally during x-ray analysis or CT scans of the chest. Several studies were done to value clinical and radiological features in order to determine whether the mass is malignant (i.e., cancerous) or benign. None of these studies can identify malignancy in the lungs. There is not an immediate and non-invasive way to determine that. The best way to manage a SPN should be surgery resection of malignant mass and avoid surgical intervention to benign one.
After imaging investigation, the diagnostics options are surgery, biopsy and CT surveillance, which one have advantages and disadvantages, that should be evaluate during total assessment and explain to patient:
- Surgery id gold standard for this kind of lesion;
- Biopsy is less invasive but has lesser diagnostic performances;
- CT surveillance avoids injury for benign mass but can be late for cancer diagnosis.
The specialist and the surgeon have several instruments available. One of this is Electro Pulmonary Nodule Scanner (EPN Scan) manufactured by ProLungdx™.
The electro pulmonary nodule scan is a reliable method to measure bioelectric properties of suspect lung lesions found by CT scan. The EPN Scan uses an established bioconductance technology with an accurate electrical current (lesser than 25 microampere) between reference electrodes situate on patient back or hands and scanner EPN scan probe.
Data are analyzed by predictive algorithms that differentiates malignant mass from benign one thanks to dielectric differences analysis detected by EPN scan.
The EPN scan relative evidence is recently provide by a study do at John Hopkins University School of Medicine and published on Journal of Thoracic Oncology. According to the authors of this prospective study of subjects with known thoracic malignancies:
“…computed bioconductance measurements discriminated between malignant lesions (29 primary lung cancers) from benign pathology (12) across a range of IPL sizes (0.8 cm and greater) with a sensitivity of 89.7% (positive predictive value 96.3%) and specificity of 91.7% (negative predictive value 78.5%). The technology seems to be effective across a range of tumor thoracic locations, cell types, and stages (Yung et al., 2012).”
Dielectric differences between malignant and benign tissues observed with EPN Scan can be attribute at cytological alterations due to malignant tumors. In case of cell structure alterations, bioconductance is different and EPN scan can assess the kind of lesion.
The literature concludes that malignant tissue has a dielectric constant and resistance different when compared to normal tissue.
Electro Pulmonary Nodule Scanner (EPN Scan) is manufactured by Fresh Medical Laboratories, Inc (DBA ProLungdx™) and exclusively distributed on the European territory by MOSS S.p.A.
Fresh Medical Laboratories, Inc (DBA ProLungdx™)
757 E South Temple, Ste 150
Salt Lake City, UT 84102 USA